Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Eur J Cancer
    June 2026
  1. ONAY M, de Valk AF, Weigert A, Kalinauskaite G, et al
    Prognostic value of DICER and CA9 expression in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Eur J Cancer. 2026;241:116776.
    >> Share

  2. OLESEN TB, Therkildsen SB, Viborg PH, Brander N, et al
    Corrigendum to 'Performance of FIT-based colorectal cancer screening in Denmark from 2014 to 2022' [Eur J Cancer 241 (June)(2026) 116788].
    Eur J Cancer. 2026;243:116873.
    >> Share

    May 2026
  3. OLESEN TB, Therkildsen SB, Viborg PH, Brander N, et al
    Performance of FIT-based colorectal cancer screening in Denmark from 2014 to 2022.
    Eur J Cancer. 2026;241:116788.
    >> Share

  4. KANHAILAL AC, Knikman JE, Zielhuis SWJ, Kodach LL, et al
    The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.
    Eur J Cancer. 2026;241:116782.
    >> Share

  5. DALAL G, Wright SJ, Malcomson L, Trenaman L, et al
    Quantifying preferences for watch-and-wait compared with surgery after a clinical complete response in locally advanced rectal cancer: A discrete choice experiment (PrefCoRe).
    Eur J Cancer. 2026;238:116589.
    >> Share

    April 2026
  6. MARCHETTI C, Gultekin M, Sassu CM, Planchamp F, et al
    ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.
    Eur J Cancer. 2026;240:116739.
    >> Share

  7. RADEMAKER E, van der Woude JM, van den Berg R, Brohet RM, et al
    Colon cancer with a peritumoural abscess: Real-world evidence on prognostic and therapeutic implications of a disregarded entity.
    Eur J Cancer. 2026;240:116705.
    >> Share

  8. DERANGERE V, Lecuelle J, Lepage C, Salem OA, et al
    Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049].
    Eur J Cancer. 2026;239:116586.
    >> Share

  9. AMBROSINI M, Gallois C, Gandini A, Lecanu A, et al
    From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.
    Eur J Cancer. 2026;239:116731.
    >> Share

  10. GALANOS LJK, Elferink MAG, Lurvink RJ, Aarts MJ, et al
    Income, treatment patterns and outcome in patients with stage IV colorectal cancer.
    Eur J Cancer. 2026;240:116732.
    >> Share

    March 2026
  11. FOURNIER E, Schaffar R, Staehelin K, Rouxel N, et al
    Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980-2021.
    Eur J Cancer. 2026;239:116707.
    >> Share

  12. HOFHEINZ RD, Weikersthal LFV, Dechow T, Depenbusch R, et al
    Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).
    Eur J Cancer. 2026;239:116689.
    >> Share

  13. WAGNER AD, Raeisi M, Rakez M, Diasio RD, et al
    Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
    Eur J Cancer. 2026;238:116694.
    >> Share

  14. KITO Y, Yamazaki K, Shoji H, Yamada T, et al
    Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).
    Eur J Cancer. 2026;238:116688.
    >> Share

  15. AL-TOMA D, Kemna R, Ali M, Zwart K, et al
    Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial.
    Eur J Cancer. 2026;238:116668.
    >> Share

    February 2026
  16. GHEDRI A, van der Baan FH, Otten JMMB, Elferink MAG, et al
    Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study.
    Eur J Cancer. 2026;237:116588.
    >> Share

  17. MAERTEN P, Defraene G, Wolthuis A, Schraepen C, et al
    Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world data.
    Eur J Cancer. 2026;234:116199.
    >> Share

  18. ZHANG X, Zhou J, Geng J, Li Y, et al
    Feasibility of ctDNA-guided precision neoadjuvant therapy in locally advanced rectal cancer: Insights from the ongoing CINTS-R trial.
    Eur J Cancer. 2026;234:116193.
    >> Share

  19. FRANKEN IA, Ketelaars SLC, Rubio-Alarcon C, Delis-van Diemen P, et al
    Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.
    Eur J Cancer. 2026;236:116262.
    >> Share

    January 2026
  20. DARAI A, de Vries S, Beets GL, Nagtegaal ID, et al
    Trends in organ preservation in rectal cancer management: A population-based study in the Netherlands.
    Eur J Cancer. 2026;232:116154.
    >> Share

  21. LUNENBERG RA, Franken IA, Braat MNGJA, Elferink MAG, et al
    The impact of mismatch repair status on accuracy of clinical staging in stage II/III rectal cancer in daily practice.
    Eur J Cancer. 2026;232:116117.
    >> Share

    December 2025
  22. WERF-'T LAM AV, Dowty JG, Italia M, Bakker AC, et al
    Cancer risks for MSH6 pathogenic variant carriers.
    Eur J Cancer. 2025;231:116098.
    >> Share

  23. VANDE KERCKHOVE FEC, van den Berg K, van Erning FN, Daniels-Gooszen AW, et al
    Implications of inaccurate lymph node staging in early and intermediate-risk rectal cancer on survival-related outcomes in a large Dutch population-based cohort.
    Eur J Cancer. 2025;231:116052.
    >> Share

    November 2025
  24. HEINRICH K, Stintzing S, Weikersthal LFV, Decker T, et al
    Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
    Eur J Cancer. 2025;232:116133.
    >> Share

  25. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    >> Share

  26. CERVANTES B, Grosnon C, Samaille T, Mas L, et al
    Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management.
    Eur J Cancer. 2025;232:116119.
    >> Share

  27. WEISS L, Stintzing S, Modest DP, Stahler A, et al
    First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (
    Eur J Cancer. 2025;232:116105.
    >> Share

  28. MIRANDOLA A, Cartry J, Bedja S, Pisareva E, et al
    Characterization of the cell-free DNA released by tumor organoids derived from colorectal cancer patients.
    Eur J Cancer. 2025;231:116097.
    >> Share

  29. BREGNI G, Leurquin B, Giasafaki P, Takemura N, et al
    Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis.
    Eur J Cancer. 2025;231:116092.
    >> Share

    October 2025
  30. KIM Y, Kim EY, Kim MY, Cho BH, et al
    Immune-enhanced machine learning approach for early detection of precancerous colorectal neoplasia: Insights from biomarkers in routine health checkups.
    Eur J Cancer. 2025;229:115786.
    >> Share

  31. YAMAMOTO K, Bando H, Misumi T, Nishikawa T, et al
    Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
    Eur J Cancer. 2025;230:116034.
    >> Share

    September 2025
  32. BERGEN ES, Le Malicot K, Taieb J
    Response to letter Re: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;230:115798.
    >> Share

  33. LIU J, Yang S, Zhang G
    Letter Re: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;230:115797.
    >> Share

  34. ONDER AH, Catli MM
    Colorectal cancer treatment commentary review.
    Eur J Cancer. 2025;230:115809.
    >> Share

  35. BATTAGLIN F, O'Neil BH, Stintzing S, Ou FS, et al
    Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
    Eur J Cancer. 2025;227:115694.
    >> Share

  36. DASARI A, Eng C, Lonardi S, Garcia-Carbonero R, et al
    Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
    Eur J Cancer. 2025;227:115641.
    >> Share

  37. LANGHEINRICH M, Gerken M, Robers G, Hansinger J, et al
    Survival benefit of adjuvant chemotherapy in elderly patients with UICC stage III colon carcinoma: A 20-year population-based German cohort study.
    Eur J Cancer. 2025;227:115583.
    >> Share

    August 2025
  38. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    >> Share

  39. HAN L, Josephs D, McDonald L, Gomm L, et al
    The effect of centralising novel cell therapies for solid cancers - a health systems planning model for Europe.
    Eur J Cancer. 2025;226:115594.
    >> Share

  40. MICHIEL ZEEUW J, Kemna R, Ali M, van Eck S, et al
    Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.
    Eur J Cancer. 2025;228:115738.
    >> Share

  41. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    >> Share

  42. ANTONIOTTI C, Marmorino F, Rossini D, Schmoll HJ, et al
    FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
    Eur J Cancer. 2025;228:115713.
    >> Share

    July 2025
  43. CIARDIELLO D, Boscolo Bielo L, Napolitano S, Cioli E, et al
    Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.
    Eur J Cancer. 2025;226:115642.
    >> Share

  44. TAIEB J, Modest DP, Fakih M, Ciardiello F, et al
    Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
    Eur J Cancer. 2025;227:115644.
    >> Share

  45. GALLOIS C, Ambrosini M, Lonardi S, Alouani E, et al
    Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Eur J Cancer. 2025;227:115645.
    >> Share

  46. BERGEN ES, Canton C, Boulin M, Le Malicot K, et al
    Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;227:115643.
    >> Share

  47. VAN DRIEL MHE, Wullaert L, Voigt KR, Outmani L, et al
    Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study.
    Eur J Cancer. 2025;226:115599.
    >> Share

    June 2025
  48. LIU R, Yin X, Bai Y, Zhong H, et al
    A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
    Eur J Cancer. 2025;226:115566.
    >> Share

  49. SHAMSEDDINE A, Turfa R, Chehade L, Zeidan YH, et al
    Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study.
    Eur J Cancer. 2025;222:115428.
    >> Share

    May 2025
  50. HAFLIGER E, Nili-Asgari R, Netter J, Taieb J, et al
    Case report of two fatal cerebral hemorrhages in patients with metastatic colorectal cancer treated with Fruquintinib.
    Eur J Cancer. 2025 May 19:115517. doi: 10.1016/j.ejca.2025.115517.
    >> Share

    April 2025
  51. MORETTO R, Rossini D, Polito MG, Antoniotti C, et al
    The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
    Eur J Cancer. 2025;222:115470.
    >> Share

  52. PIZZAMIGLIO M, Soulabaille A, Lahlou W, Pilla L, et al
    Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.
    Eur J Cancer. 2025;222:115471.
    >> Share

  53. NORONHA MM, Costa Almeida LF, Cappellaro AP, Silva LFLD, et al
    Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials.
    Eur J Cancer. 2025;222:115476.
    >> Share

  54. JORGENSEN SF, Njor SH, Nevala A, Palsson B, et al
    Nordic colorectal cancer screening programmes: A comparison of organization, operation, and quality indicators.
    Eur J Cancer. 2025;222:115444.
    >> Share

  55. WEISS L, Stintzing S, Stahler A, Benedikt Westphalen C, et al
    Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2025;221:115399.
    >> Share

    March 2025
  56. HOLCH JW, Ohnmacht AJ, Stintzing S, Heinrich K, et al
    FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
    Eur J Cancer. 2025;220:115388.
    >> Share

  57. MORETTO R, Boccaccio C, Landi M, Masi G, et al
    Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorit
    Eur J Cancer. 2025;218:115261.
    >> Share

  58. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    >> Share

    February 2025
  59. POUMEAUD F, Valentin T, Fares N, Segier B, et al
    Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
    Eur J Cancer. 2025;216:115196.
    >> Share

  60. QIU X, Zhou J, Qiu H, Shen Z, et al
    A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R.
    Eur J Cancer. 2025;216:115156.
    >> Share

    January 2025
  61. SOBRERO A, Dasari A, Aquino J, Lonardi S, et al
    Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
    Eur J Cancer. 2025;218:115268.
    >> Share

  62. WANG DS, Pat Fong W, Wen L, Cai YY, et al
    Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.
    Eur J Cancer. 2025;214:115154.
    >> Share

    December 2024
  63. CARBONE F, Spinelli A, Ciardiello D, Realis Luc M, et al
    Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
    Eur J Cancer. 2024;215:115172.
    >> Share

  64. TOUGERON D, Bibeau F, Chibaudel B, Kim S, et al
    Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
    Eur J Cancer. 2024;213:115082.
    >> Share

    November 2024
  65. HIRANO H, Kataoka K, Yamaguchi T, Wagner AD, et al
    Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
    Eur J Cancer. 2024;214:115139.
    >> Share

  66. DUNN C, Shapiro J, Lee M, Wong R, et al
    Measuring quality in the care of metastatic colorectal cancer utilising available registry data: A modified Delphi study.
    Eur J Cancer. 2024;214:115142.
    >> Share

  67. XIAO A, Li X, Wang C, Ye J, et al
    Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.
    Eur J Cancer. 2024;213:115111.
    >> Share

  68. SUN L, Xu Y, Chen N, Zhang C, et al
    Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.
    Eur J Cancer. 2024;213:115109.
    >> Share

  69. FRYDENDAHL A, Nors J, Rasmussen MH, Henriksen TV, et al
    Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.
    Eur J Cancer. 2024;211:114314.
    >> Share

    October 2024
  70. STINTZING S, Yoshino T
    Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;210:114298.
    >> Share

  71. FOKAS E, Williams H, Diefenhardt M, Lin S, et al
    Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.
    Eur J Cancer. 2024;210:114291.
    >> Share

    September 2024
  72. SMABERS LP, Huismans MA, van Nieuwenhuijzen N, Minnema MC, et al
    Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis.
    Eur J Cancer. 2024;212:115059.
    >> Share

  73. MARGALIT O, Stemmer A, Chapin WJ, Shacham-Shmueli E, et al
    Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients.
    Eur J Cancer. 2024;212:114336.
    >> Share

  74. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    >> Share

    August 2024
  75. AMBROSINI M, Tougeron D, Modest D, Guimbaud R, et al
    BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
    Eur J Cancer. 2024;210:114290.
    >> Share

  76. XIE Z, Lin H, Huang Y, Wang X, et al
    BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer.
    Eur J Cancer. 2024;210:114278.
    >> Share

  77. ZHANG P, Han Y, Cai Z, Cao D, et al
    Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024 Aug 6:114266. doi: 10.1016/j.ejca.2024.114266.
    >> Share

  78. MICHIEL ZEEUW J, Wesdorp NJ, Ali M, Bakker AJJ, et al
    Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation.
    Eur J Cancer. 2024;207:114185.
    >> Share

    July 2024
  79. FRANKEN IA, van der Baan FH, Vink GR, May AM, et al
    Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months.
    Eur J Cancer. 2024;208:114207.
    >> Share

    June 2024
  80. MERCIER L, Delaye M, Fuerea A, Ducreux M, et al
    Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer.
    Eur J Cancer. 2024;208:114193.
    >> Share

  81. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    >> Share

  82. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Corrigendum to "Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021'' Volume 205, July 2024, 114104.
    Eur J Cancer. 2024 Jun 11:114155. doi: 10.1016/j.ejca.2024.114155.
    >> Share

  83. COHEN R, Raeisi M, Chibaudel B, Shi Q, et al
    Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Eur J Cancer. 2024;207:114160.
    >> Share

  84. ZWART WH, Temmink SJD, Hospers GAP, Marijnen CAM, et al
    Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.
    Eur J Cancer. 2024;204:114044.
    >> Share

    May 2024
  85. CHEN C, Feng YS, Wang Z, Gupta M, et al
    Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer.
    Eur J Cancer. 2024;207:114147.
    >> Share

  86. TAIEB J, Basile D, Seligmann J, Argiles G, et al
    Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.
    Eur J Cancer. 2024;206:114118.
    >> Share

  87. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021.
    Eur J Cancer. 2024;205:114104.
    >> Share

  88. MOREAU M, Alouani E, Flecchia C, Falcoz A, et al
    A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
    Eur J Cancer. 2024;202:114033.
    >> Share

  89. VAN GEFFEN EGM, Langhout JMA, Hazen SJA, Sluckin TC, et al
    Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
    Eur J Cancer. 2024;202:114021.
    >> Share

    March 2024
  90. TAKASHIMA A, Garcia-Alfonso P, Manneh R, Besen AA, et al
    Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
    Eur J Cancer. 2024;205:114036.
    >> Share

  91. BARBE R, Belkouchi Y, Menu Y, Cohen R, et al
    Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
    Eur J Cancer. 2024;202:114020.
    >> Share

  92. SPIEKMAN IAC, Zeverijn LJ, Geurts BS, Verkerk K, et al
    Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Eur J Cancer. 2024;202:113988.
    >> Share

  93. LI L
    Comment on: Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
    Eur J Cancer. 2024;202:113982.
    >> Share

  94. YOSHINO T, Hooda N, Younan D, Muro K, et al
    A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;202:113975.
    >> Share

    November 2023
  95. SHKURTI J, van den Berg K, van Erning FN, Lahaye MJ, et al
    Diagnostic accuracy of CT for local staging of colon cancer: A nationwide study in the Netherlands.
    Eur J Cancer. 2023;193:113314.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016